Enhanced B cell cytotoxicity of CDIM binding antibody
First Claim
1. A method of treating a human patient suffering from a condition characterized by a hyperproliferation of B cells, comprising contacting said B cells with (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic agent.
7 Assignments
0 Petitions
Accused Products
Abstract
Formulations and methods of treating human patients suffering from a condition characterized by lymphoid cancer, autoimmune disease or B cell hyperproliferation are disclosed, the treatment comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic agent, including a chemotherapeutic agent, radioactive isotope, cytotoxic antibody, immunoconjugate, ligand conjugate, immunosuppressant, cell growth regulator and/or inhibitor, toxin, or mixtures thereof, including agents that disrupt the cytoskeleton of B cells, particularly vinca alkaloids or colchicine.
-
Citations
80 Claims
- 1. A method of treating a human patient suffering from a condition characterized by a hyperproliferation of B cells, comprising contacting said B cells with (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic agent.
-
52. A method of treating a human patient suffering from a condition characterized by lymphoid cancer, comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a chemotherapeutic agent.
-
53. A method of treating a human patient suffering from a condition characterized by lymphoid cancer, comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic antibody having specific binding for a cell surface receptor on a B cell.
- 54. A method of augmenting the B cell cytotoxicity of an antibody that binds a CDIM epitope, comprising contacting B cells with the antibody that binds a CDIM epitope and an agent that disrupts the cytoskeleton of B cells.
-
60. A method of treating an autoimmune disease in a mammal, comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a chemotherapeutic agent, an antibody having specific binding for cell surface receptors on a B cell, an immunosuppressant, a cell growth regulator and/or inhibitor, or mixtures thereof.
- 61. A method of killing malignant B cells that are resistant to chemotherapeutic agents, cell growth regulators and/or inhibitors, or cytotoxic antibodies, comprising contacting said malignant B cells with an antibody having specific binding for CDIM epitopes on a B cell.
-
63. A method of killing malignant B cells that are resistant to an antibody having specific binding for CDIM epitopes on a B cell, comprising treating said B cells with a chemotherapeutic agent and an antibody having specific binding for CDIM epitopes on the B cells.
-
64. A method of treating a disease or disorder characterized by a hyperproliferation of B cells, comprising contacting the B cells with an amount of an antibody having specific binding for CDIM epitopes on a B cell sufficient to permeabilize the B cells.
-
65. A method for reducing tumor load in a patient suffering from lymphoid cancer refractory to reinduction therapy, comprising administering a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, wherein said treatment allows the patient to undergo subsequent reinduction therapy.
-
66. A method for augmenting the cytotoxicity of an anti-B cell antibody, comprising administering a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell.
- 67. A pharmaceutical formulation for parenteral injection comprising a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell.
-
69. A kit for treating a patient suffering from a condition characterized by a hyperproliferation of B cells comprising:
-
(a) an amount of an antibody having specific binding for CDIM epitopes on a B cell sufficient to permeabilize the B cells in the patient, (b) a therapeutically effective amount of a cytotoxic agent effective to treat the condition characterized by the hyperproliferation of B cells.
-
- 70. A method for purging the bone marrow of a patient suffering from lymphoid cancer of malignant B cells prior to reimplantation of the bone marrow in the patient after myeloablative therapy, comprising treating the bone marrow ex vivo with a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell.
- 72. A method for treating a human patient suffering from a condition characterized by hyperproliferation of B cells, comprising contacting said B cells with (1) a cytotoxic amount of the anti-CDIM antibody mAb 216 or Y2K, and (2) an anti-CD20 antibody.
- 75. A method for treating a human patient suffering from a condition characterized by hyperproliferation of B cells, comprising contacting said B cells with (1) a cytotoxic amount of the anti-CDIM antibody mAb 216 or Y2K, and (2) an anti-CD52 antibody.
- 78. A method for treating a human patient suffering from a condition characterized by hyperproliferation of B cells, comprising contacting said B cells with (1) a cytotoxic amount of the anti-CDIM antibody mAb 216 or Y2K, and (2) an anti-CD22 antibody.
Specification